Improving outcomes in patients with advanced renal cell carcinoma

Jeffrey A. Sosman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


The emergence of targeted therapies for advanced renal cell carcinoma has been a dramatic turning point in improving outcomes for the majority of patients with this disease. In study populations comprising primarily good- and intermediate-risk patients with clear cell renal cell carcinoma and prior nephrectomy, prolonged progression-free survival was demonstrated for three angiogenesis-targeted agents: sunitinib (compared with interferon [IFN]), bevacizumab plus IFN (vs IFN alone) and sorafenib (vs placebo in cytokine-refractory patients). As a first-line treatment for patients with multiple poor-risk factors, temsirolimus, which inhibits mTOR, has improved not only progression-free survival compared with IFN but, more importantly, overall survival. Further studies are needed to determine whether combinations and/or sequencing of these targeted agents can further improve outcomes.

Original languageEnglish (US)
Pages (from-to)481-490
Number of pages10
JournalExpert review of anticancer therapy
Issue number3
StatePublished - Mar 1 2008


  • Mammalian target of rapamycin
  • Renal cell carcinoma
  • Survival
  • Targeted therapies
  • Vascular endothelial growth factor
  • mTOR

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Improving outcomes in patients with advanced renal cell carcinoma'. Together they form a unique fingerprint.

Cite this